Announcements Trials
Browse Landscape

Status

No longer available 3Available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Expanded_access 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3Recurrence 1

Interventions

trametinib 4nilotinib 4elotuzumab 4dabrafenib 4Amifampridine 4regorafenib 3pembrolizumab 3midostaurin 3fludarabine phosphate 3fludarabine 3Nivolumab 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Cyclophosphamide 3Crizotinib 3Bortezomib 3Axitinib 3venetoclax 2veliparib 2tazemetostat 2talimogene laherparepvec 2navitoclax 2gallium 68 PSMA-11 2ceritinib 2carbon-11 acetate 2aldesleukin 2Whole-Body Irradiation 2Trabectedin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
No longer available × Expanded_access × Bortezomib × Clear all
NCT02666209 2017-08-28

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

Dana-Farber Cancer Institute

No longer available
Plasma cell

Multiple Myeloma

NCT00799539 2015-12-02

A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients

Janssen-Ortho Inc., Canada

No longer available
Plasma cell

Multiple Myeloma

NCT00063791 2007-02-14

A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE

Millennium Pharmaceuticals, Inc.

No longer available
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡